CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
SAGA Diagnostics›
Library
SAGA Diagnostics

SAGA Diagnostics

Operating Status: Acquired Subsidiary

Developer of ultra-sensitive, tumor-informed blood tests for molecular residual disease detection, anchored by the flagship Pathlight MRD platform.

Operating headquarters
Research Triangle Park, NC, US🇺🇸
Loading
Overview
Compare
Employees
Library

SAGA Diagnostics - Library

sagadiagnostics.com·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Product

5 pages
  1. Biopharma Partnering/biopharma-partnering

    Pathlight is being used in clinical studies by multiple top 10 pharmaceutical companies and leading academic institutions and national cancer centers.

  2. Clinicians and Providers/clinicians-and-providers

    Fast Answers. Meaningful Insights. Pathlight, the ultra-sensitive MRD platform from SAGA, provides earlier detection to inform patient-provider decisions.

  3. Our Science/our-science

    Pathlight, the company’s flagship blood-based, multi-cancer MRD platform, overcomes one of the toughest challenges in oncology

  4. Patients/patients

    Information for Patients and Caregivers. After a cancer diagnosis, many questions can arise. The results of an MRD test can help provide answers

Blog

3 pages
  1. News Archives/category/news

    Key poster presentations highlight the expanding body of evidence supporting Pathlight™, SAGA’s tumor-informed structural variant (SV)-based circulating tumor DNA (ctDNA) platform, across both metastatic and localized settings.

  2. Posters and Publications/posters-and-publications

    Posters and Publications - View the latest publications.

  3. Publications Archives/category/publications

Press

6 pages
  1. SAGA Diagnostics Showcases New Pathlight MRD Data at SABCS 2025/saga-diagnostics-showcases-new-pathlight-mrd-data-at-sabcs-2025
  2. SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes/saga-diagnostics-announces-medicare-coverage-for-pathlight-mrd-test-in-breast-cancer-across-all-subtypes
  3. SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection/saga-diagnostics-announces-u-s-commercial-launch

    SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection

  4. SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer/saga-diagnostics-launches-ultrasensitive-pathlight-mrd-test-in-colorectal-cancer

Team

1 page
  1. Our Team/our-team

    Never losing sight of our guiding purpose to empower treatment decisions with greater insight and confidence.

About

1 page
  1. About Us/about-us

    SAGA has developed a next-generation MRD platform specifically designed to overcome the key limitations of earlier methods

Contact

1 page
  1. Contact Us/contact-us

    Contact us to learn more about our leading MRD technology, our approach to partnering, or to order a test.

Homepage

1 page
  1. Homepage/

    SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence.

Privacy

4 pages
  1. Consumer Health Data Privacy Policy/consumer-health-data-privacy-policy

    Consumer Health Data Privacy Policy Consumer Health Data Privacy Policy Last Updated: March 18, 2025 This Consumer Health Data Privacy Policy provides information regarding how SAGA Diagnostics US, Inc. (“SAGA,” “we,” “our,” or “us”) process “consumer health data” as defined by applicable consumer health data privacy laws. In the event of a conflict between SAGA’s […]

  2. Cookie Notice/cookie-notice

    Cookie Notice Last Updated: April 1, 2025 This Cookie Notice describes how SAGA Diagnostics US, Inc., and its subsidiaries and vendors, and other third parties acting on our behalf may use digital tracking technologies on our Sagadiagnostics.com website, or any of our other websites or online services (“Services”) that link to this Notice. For more information about our […]

  3. European Applicant Privacy Notice/european-applicant-privacy-notice

    European Applicant Privacy Notice Effective Date: March 18, 2025 SAGA Diagnostics US, Inc., located at 860 Aviation Parkway, Ste 300, Morrisville, NC 27560, and its affiliated companies in the United States and Europe, including SAGA Dx, Inc., SAGA Diagnostics AB, and SAGA Diagnostics UK, Ltd., (collectively “SAGA”) respect your right to privacy and are committed […]

  4. European Data Privacy Statement/european-data-privacy-statement

    European Data Privacy Statement Effective Date: March 18, 2025 SAGA Diagnostics US, Inc., located at 860 Aviation Parkway, Ste 300, Morrisville, NC 27560, and its affiliated companies in the United States and Europe, including SAGA DX, Inc., SAGA Diagnostics AB, and SAGA Diagnostics UK, Ltd., (collectively “SAGA”), respect your right to privacy, and are committed […]